Amrutanjan Health Care Ltd
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]
- Market Cap ₹ 1,844 Cr.
- Current Price ₹ 638
- High / Low ₹ 775 / 556
- Stock P/E 41.9
- Book Value ₹ 90.6
- Dividend Yield 0.72 %
- ROCE 19.3 %
- ROE 14.3 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 24.6%
Cons
- Stock is trading at 7.04 times its book value
- The company has delivered a poor sales growth of 11.5% over past five years.
- Earnings include an other income of Rs.16.2 Cr.
- Working capital days have increased from 79.3 days to 117 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
128 | 128 | 131 | 154 | 174 | 207 | 220 | 253 | 261 | 333 | 406 | 380 | 394 | |
108 | 109 | 108 | 130 | 143 | 178 | 192 | 222 | 231 | 258 | 326 | 335 | 346 | |
Operating Profit | 20 | 19 | 23 | 25 | 32 | 29 | 28 | 31 | 31 | 75 | 80 | 45 | 49 |
OPM % | 16% | 15% | 18% | 16% | 18% | 14% | 13% | 12% | 12% | 22% | 20% | 12% | 12% |
5 | 4 | 3 | 5 | 6 | 7 | 8 | 7 | 8 | 11 | 15 | 15 | 16 | |
Interest | 3 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Depreciation | 3 | 3 | 3 | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 6 |
Profit before tax | 19 | 18 | 21 | 26 | 35 | 34 | 33 | 35 | 34 | 82 | 91 | 54 | 59 |
Tax % | 29% | 32% | 32% | 35% | 35% | 35% | 39% | 29% | 27% | 25% | 26% | 26% | |
13 | 12 | 15 | 17 | 22 | 22 | 20 | 25 | 25 | 61 | 67 | 40 | 44 | |
EPS in Rs | 4.57 | 4.15 | 4.97 | 5.86 | 7.68 | 7.47 | 6.84 | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 | 15.15 |
Dividend Payout % | 33% | 36% | 32% | 30% | 25% | 26% | 22% | 26% | 24% | 20% | 20% | 34% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 12% |
3 Years: | 13% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 16% |
3 Years: | 17% |
TTM: | 5% |
Stock Price CAGR | |
---|---|
10 Years: | 25% |
5 Years: | 16% |
3 Years: | 1% |
1 Year: | 4% |
Return on Equity | |
---|---|
10 Years: | 20% |
5 Years: | 22% |
3 Years: | 24% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 78 | 85 | 94 | 102 | 118 | 113 | 126 | 143 | 156 | 213 | 262 | 288 | 259 |
22 | 13 | 6 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | |
22 | 26 | 22 | 25 | 28 | 34 | 38 | 42 | 44 | 57 | 84 | 70 | 92 | |
Total Liabilities | 124 | 127 | 124 | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 355 |
19 | 17 | 15 | 13 | 22 | 27 | 28 | 26 | 26 | 23 | 28 | 49 | 50 | |
CWIP | 1 | 1 | 1 | 4 | 1 | 1 | 0 | 0 | 0 | 2 | 17 | 1 | 0 |
Investments | 34 | 30 | 14 | 14 | 10 | 10 | 8 | 18 | 18 | 18 | 13 | 5 | 5 |
70 | 79 | 95 | 100 | 116 | 115 | 131 | 144 | 161 | 232 | 291 | 307 | 300 | |
Total Assets | 124 | 127 | 124 | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 355 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
13 | 8 | 18 | 19 | 21 | 8 | 19 | 21 | 18 | 91 | 52 | 20 | |
4 | 16 | 16 | -5 | 1 | -0 | -8 | -11 | -14 | -88 | -36 | -2 | |
-27 | -17 | -14 | -12 | -11 | -5 | -9 | -7 | -12 | -7 | -17 | -15 | |
Net Cash Flow | -9 | 8 | 20 | 2 | 12 | 3 | 2 | 3 | -7 | -4 | -1 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 37 | 78 | 66 | 62 | 55 | 51 | 46 | 47 | 37 | 19 | 34 | 32 |
Inventory Days | 59 | 44 | 45 | 44 | 44 | 44 | 40 | 45 | 74 | 45 | 53 | 58 |
Days Payable | 68 | 55 | 44 | 46 | 51 | 110 | 102 | 92 | 98 | 106 | 122 | 95 |
Cash Conversion Cycle | 27 | 67 | 67 | 61 | 48 | -15 | -16 | 0 | 13 | -41 | -35 | -6 |
Working Capital Days | 33 | 57 | 54 | 42 | 45 | 80 | 26 | 30 | 71 | 29 | 92 | 117 |
ROCE % | 19% | 20% | 24% | 26% | 29% | 28% | 25% | 25% | 23% | 44% | 38% | 19% |
Documents
Announcements
-
Compliance Certificate For The Period Ended March 31, 2024
8 Apr - Compliance Certificate'' duly signed by the Compliance officer and authorized representative of the share transfer agent.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr
- Closure of Trading Window 26 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 7 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
High Market Share in Modern Trade
Amrutanjan has maintained the No. 1 rank in Modern Trade in Head Category with the volume market share of 41.1%* in CY19. [1]